CSIMarket
 

Lite Strategy Inc   (NASDAQ: LITS)

Lite Strategy Inc 's

Competitiveness




 

LITS Sales vs. its Competitors Q3 2026



Comparing the current results to its competitors, Lite Strategy Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.12 %, recorded in the same quarter.

List of LITS Competitors





Revenue Growth Comparisons




Net Income Comparison


Lite Strategy Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 386.65 %

<<  LITS Stock Performance Comparisons


Lite Strategy Inc 's Comment on Competition and Industry Peers


The company's drug candidates face competition from numerous entities, including pharmaceutical and biotechnology companies, universities, and public and private research institutions. Competitors have products or drug candidates at various stages of pre-clinical or clinical development targeting the same therapeutic indications. Some competitors' drug candidates are more advanced and may reach commercialization sooner. Many competitors possess greater capital resources, larger research and development staffs and facilities, and more experience in drug development, regulation, manufacturing, marketing, and commercialization. They also compete in recruiting clinical study sites and patients, securing development and commercialization partners, and licensing technologies that could impact the competitiveness of the company's products.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Lite Strategy Inc




Tuhura Biosciences Inc
Share Performance



-9.15%
This Quarter



Tuhura Biosciences Inc
Profile

The company develops novel immuno-oncology therapeutics aimed at overcoming resistance to cancer immunotherapies.

More about Tuhura Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 130.166 mill. $ - mill. $ -30.624 mill.


Palvella Therapeutics Inc
Share Performance



+180.99%
One Year



Palvella Therapeutics Inc
Profile

Palvella Therapeutics, Inc. develops product candidates targeting rare skin diseases and vascular malformations.

More about Palvella Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,158.601 mill. $ - mill. $ -61.696 mill.


Nucana Plc
Share Performance



-62.43%
This Year



Nucana Plc
Profile

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

More about Nucana Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -29.353 mill.


Decoy Therapeutics Inc
Share Performance



0.00%
Over The Past 5 Days



Decoy Therapeutics Inc
Profile

Decoy Therapeutics Inc. develops peptide conjugate therapeutics utilizing artificial intelligence and machine learning technologies.

More about Decoy Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.601 mill. $ - mill. $ -13.034 mill.


Inhibitor Therapeutics Inc
Share Performance



0.00%
This Year



Inhibitor Therapeutics Inc
Profile

Inhibitor Therapeutics Inc's business model focuses on developing and commercializing innovative inhibitors for targeted therapies.

More about Inhibitor Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15.043 mill. $ - mill. $ -3.308 mill.

69 more competitors available

Sign in to see all competitors

Sources: Lite Strategy Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lite Strategy Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.